Lilly Company Profile

What is the competitive landscape for LILLY

LILLY has one hundred and five approved drugs.

Summary for Lilly

US Patents:	0
Tradenames:	85
Ingredients:	81
NDAs:	105

Drugs and US Patents for Lilly

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CORDRAN N	flurandrenolide; neomycin sulfate	OINTMENT;TOPICAL	050345-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	AEROLONE	isoproterenol hydrochloride	SOLUTION;INHALATION	007245-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	BACITRACIN	bacitracin	OINTMENT;OPHTHALMIC	060687-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	HISTAMINE PHOSPHATE	histamine phosphate	INJECTABLE;INJECTION	000734-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	SECONAL SODIUM	secobarbital sodium	SUPPOSITORY;RECTAL	086530-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-004	Nov 26, 2002		DISCN	Yes	No

Expired US Patents for Lilly

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	RE38968
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-003	Dec 24, 2003	5,229,382*PED
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,710,285
Lilly	GEMZAR	gemcitabine hydrochloride	INJECTABLE;INJECTION	020509-002	May 15, 1996	5,464,826*PED
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,731,327
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-004	Aug 3, 2004	5,508,276*PED

Paragraph IV (Patent) Challenges for LILLY drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Capsules	40 mg		2012-05-10
	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg		2005-01-10
	For Injection	200 mg/vial		2005-11-01
	For Injection	2 g/vial		2007-08-24
	For Injection	500 mg/vial		2008-02-04
	For Injection	750 mg/vial		2016-10-06
	Tablets	2.5 mg		2008-10-14
	Delayed-release Capsules	20 mg, 30 mg and 60 mg		2008-08-04
	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg		2007-05-29
	Capsules	3 mg/25 mg		2008-05-08
	For Injection	1g/vial		2005-11-14
	For Injection	100 mg/vial		2008-07-01
	For Injection	1000 mg/vial		2012-06-27
	Injection	250 mcg/mL, 2.4 mL prefilled Pen		2015-07-27
	Tablets	5 mg, 10 mg and 20 mg		2007-11-21

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Lilly
• Lilly Res Labs

Lilly’s Market Position, Strengths, and Strategic Insights in the Pharmaceutical Sector

Last updated: February 20, 2026

How Does Lilly Stand in the Global Pharmaceutical Market?

Eli Lilly and Company (Lilly) ranks among the top U.S.-based pharmaceutical firms, with a focus on neuroscience, oncology, diabetes, and immunology. As of 2022, Lilly reported revenues of approximately $28.3 billion, positioning it as a mid-tier leader with growing influence in specialty therapeutics.

Revenue and Market Share

Year	Revenue (USD billion)	Global Rank (Pharma)	Notable Market Segments
2022	28.3	14th	Oncology, Diabetes, Neuroscience
2021	25.2	16th	Oncology, Immunology
2020	23.4	17th	Diabetes, Oncology

Lilly's revenue growth stems mainly from key drug launches and portfolio expansion in specialty areas. The firm's estimated global market share hovers around 2%, with higher concentrations in developed markets like the U.S. and Europe.

What Are Lilly’s Core Strengths?

Robust R&D Pipeline

Lilly invests annually approximately 20% of its revenue into R&D, totaling over $5.5 billion in 2022. This funding supports novel therapies, particularly in immunology and oncology. Its pipeline includes:

• Donanemab: Alzheimer's disease experimental drug in late-stage trials.
• Verzenio: Breast cancer medication with strong sales growth.
• Tirzepatide: Promising in type 2 diabetes and obesity.

Portfolio Diversification

Lilly maintains a diversified portfolio with leading products across multiple therapeutic areas. Key commercial drugs include:

• Humalog: Insulin analog for diabetes.
• Olumiant: Rheumatoid arthritis treatment.
• Trulicity: GLP-1 receptor agonist for glycemic control.

This diversification mitigates risks associated with patent expirations and market fluctuations in individual segments.

Strategic Collaborations and Acquisitions

Lilly pursues strategic alliances to accelerate innovation:

• In 2021, Lilly acquired Prevail Therapeutics for $880 million, boosting gene therapy capabilities.
• Collaborations with AbCellera, BeiGene, and others deepen oncology and immunology research.

Regulatory Approvals and Launches

Lilly has secured approximately 20 new drug approvals over the past five years, including expanding indications for its blockbuster products. Its ability to navigate regulatory pathways enhances its competitive positioning.

What Strategic Challenges or Risks Does Lilly Face?

Patent Expirations and Generic Competition

Key drugs like Humalog face generic competition, potentially reducing revenue by an estimated 15% annually post-patent expiry. The firm actively seeks pipeline and new market launches to offset these losses.

Pricing and Healthcare Policy

Lilly's revenue is sensitive to pricing pressures, especially in the U.S., where drug pricing debates and reimbursement policies influence margins. Changes in Medicare and Medicaid policies could impact profits.

Competition from Larger and Biotech Firms

Lilly competes with firms like Pfizer, Novartis, and emerging biotechs. Innovative therapies from competitors threaten Lilly's market share, especially in oncology and immunology.

Regulatory Risks and Clinical Trial Failures

Failure in late-stage trials or regulatory setbacks can delay or cancel promising therapies. The firm maintains rigorous trial design and regulatory engagement to mitigate these risks.

How Does Lilly’s Strategic Position Compare to Peers?

Company	Revenue (2022)	Focus Areas	Pipeline Strength	R&D Investment (% of Revenue)
Lilly	28.3B	Oncology, Diabetes, Immunology	50+ drugs in development, high success rate	20%
Pfizer	100.3B	Vaccines, Oncology, Rare Diseases	Leading COVID-19 vaccine and pipeline	14%
Novartis	51.9B	Oncology, Ophthalmology, Neuroscience	Significant gene therapy portfolio	19%
Boehringer Ingelheim	21.2B	Respiratory, Cardiovascular, Oncology	Focused pipeline, strong research capabilities	20%

Lilly’s strategic focus on high-growth therapeutic areas and pipeline innovation positions it favorably relative to peers, despite a smaller revenue base.

What Are the Long-term Strategic Opportunities?

Focus on Biotechnology and Gene Therapy

Recent acquisitions, such as Prevail Therapeutics, signal a strategic shift toward gene therapy and advanced biologics. Lilly aims to leverage these technologies to develop personalized, curative treatments.

Expansion in Emerging Markets

Capitalize on growth in Asia-Pacific, Latin America, and Africa by establishing manufacturing hubs and expanding access programs. This could create new revenue streams and reduce dependence on mature markets.

Digital and Data-Driven Medicine

Investments in digital health platforms, real-world evidence, and artificial intelligence can optimize clinical trials and commercialization strategies, reducing time-to-market and costs.

Broaden Oncology Portfolio

Continued innovation in targeted therapies, immunotherapies, and combination treatments aligns with industry trends. Strategic collaborations will support pipeline expansion.

Key Takeaways

• Lilly maintains a stable, diversified portfolio with a focus on high-growth therapeutics.
• The company's R&D investment supports a strong pipeline, especially in oncology and immunology.
• Patent expirations pose revenue risks; continued pipeline innovation remains crucial.
• Strategic acquisitions and alliances strengthen its biologic and gene therapy capabilities.
• Competitive pressures require nimbleness in pricing, regulatory navigation, and market expansion.

FAQs

1. How does Lilly's R&D expenditure compare to competitors?
Lilly invests approximately 20% of its revenue into R&D, higher than Pfizer’s 14%, aligning with its focus on innovative biologics and personalized medicine.

2. What are Lilly’s most promising pipeline candidates?
Donanemab for Alzheimer's, Tirzepatide for diabetes and obesity, and late-stage oncology drugs like Lumakras are among the most promising.

3. How vulnerable is Lilly to patent cliffs?
Drugs like Humalog face patent expirations, which can reduce revenue by 10-15% annually. Diversification and pipeline growth mitigate this risk.

4. What markets provide growth opportunities outside the U.S.?
Emerging markets in Asia-Pacific, Latin America, and Africa offer growth potential through increased healthcare access and local manufacturing.

5. How does Lilly's competitive strategy differ from larger peers?
Lilly focuses heavily on biologics and neuroscience, markets with less generic competition, while larger peers diversify across broader therapeutic and product categories.

---

References

[1] Eli Lilly and Company 2022 Annual Report. (2023). Retrieved from https://lilly.com/investors/annual-reports [2] IQVIA. (2022). Top 20 Global Pharmaceutical Companies by Revenue.
[3] EvaluatePharma. (2022). World Preview 2022.
[4] Deloitte. (2021). Global Life Sciences Outlook.